Melane Sampson, Author at BioTuesdays

Uncategorized

Arch scientists publish new data linking cytokine IL-32 to DKD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) announced a scientific team, led by principal scientist Dr. Justin Chun at the University of Calgary, report in the peer-reviewed journal Inflammation Research that...

February 9, 2026

Developments

PreveCeutical files patent for delivery of CNS-active agents

PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF) has filed an international patent application for the delivery of CNS-active therapeutic agents covering methods and formulations aimed at addressing treatment challenges...

February 9, 2026

Executive Moves

Rita Johnson-Greene joins Ocugen as CFO

Ocugen (NASDAQ: OCGN) has appointed Rita Johnson-Greene as chief financial officer (CFO). Ms. Johnson-Greene brings more than 20 years of healthcare experience to the role. Most recently, she served as chief operating...

February 9, 2026

Developments

Exicure reports publication highlighting Phase 2 burixafor data showing rapid stem cell mobilization

Exicure (NASDAQ: XCUR) announced that Annals of Hematology has published results from a Phase 2 clinical study demonstrating rapid stem cell mobilization with burixafor (GPC-100/TG-0054)—a highly selective CXCR4...

February 6, 2026

Developments

Cognition lengthens Zervimesine program in DLB

Cognition Therapeutics (NASDAQ: CGTX) has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB) from the original 12 months to include several more months of treatment. According...

February 6, 2026

Developments

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

Profound Medical (NASDAQ:PROF; TSX:PRN) announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve Procedure. The MRI-guided therapy provides women with a non-surgical...

February 5, 2026

Developments

JPO grants patent to Marvel for MB-204

Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) has been granted a patent for its lead therapeutic candidate MB-204 by the Japanese Patent Office (JPO) covering composition of matter and methods of use claims. MB-204 is a...

February 4, 2026

Developments

FDA grants Fast Track Designation to Cumberland’s ifetroban DMD program

Cumberland Pharmaceuticals (NASDAQ: CPIX) has received Fast Track Designation from the FDA for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. The FDA has...

February 4, 2026

Executive Moves

LeonaBio appoints industry veteran Mark F. Kubic as CBO

LeonaBio (NASDAQ: LONA) has appointed Mark F. Kubic as chief business officer (CBO) to lead the company’s business development strategy and execution. Mr. Kubik served as a strategic consultant to LeonaBio and played a...

February 3, 2026

Developments

FDA clears Nanox’s TAP2D image enhancement technology

Nanox (NASDAQ: NNOX) has announced receiving FDA 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. According to Nanox, the FDA...

February 3, 2026

Author - Melane Sampson

Arch scientists publish new data linking cytokine IL-32 to DKD

PreveCeutical files patent for delivery of CNS-active agents

Rita Johnson-Greene joins Ocugen as CFO

Exicure reports publication highlighting Phase 2 burixafor data showing rapid stem cell mobilization

Cognition lengthens Zervimesine program in DLB

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

JPO grants patent to Marvel for MB-204

FDA grants Fast Track Designation to Cumberland’s ifetroban DMD program

LeonaBio appoints industry veteran Mark F. Kubic as CBO

FDA clears Nanox’s TAP2D image enhancement technology

Subscribe